Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
about
Cooperating transcription factors mediate the function of estrogen receptorRetinoids induce cellular senescence in breast cancer cells by RAR-β dependent and independent pathways: Potential clinical implications (Review)ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionAll-trans-retinoic Acid Modulates the Plasticity and Inhibits the Motility of Breast Cancer Cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ).Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.RARRES3 suppressed metastasis through suppression of MTDH to regulate epithelial-mesenchymal transition in colorectal cancer.MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cellsThe CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathwayActivation of RARα induces autophagy in SKBR3 breast cancer cells and depletion of key autophagy genes enhances ATRA toxicity.CrossLink: a novel method for cross-condition classification of cancer subtypesGene expression changes as markers of early lapatinib response in a panel of breast cancer cell linesMining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach.Pan-cancer analyses of the nuclear receptor superfamilyReversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cellsTargeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapyEnhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures.Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid.Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells.Retinoids and breast cancer: new clues to increase their activity and selectivity.RA and ω-3 PUFA co-treatment activates autophagy in cancer cells.A novel computational approach for drug repurposing using systems biology.Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells.Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer
P2860
Q26996464-0FED09FF-CB9B-40C4-81D5-AB9657B82F2FQ28081010-0355E228-ACFB-436C-9304-4AAB66D781ECQ33829405-7E339CD8-F6DF-45DC-99AC-F006BFF398F0Q35859452-3CCCF154-B7DA-4053-B842-11CBEEAE9D6FQ35904255-510E62E4-02DE-4623-9F22-2710827F7D59Q35929836-E4D18E3E-08E9-437D-A2A3-B162A1D22622Q35955244-92A396A9-86A5-4C24-BA00-965C6B09F2A0Q36010739-B51ECDC4-20D2-481C-AD1B-89CE6799FB64Q36022328-9CCE2661-6808-48C4-8733-48F3A9D3C39EQ36111302-4672DB03-539F-421D-A651-E960B5948BBCQ36226540-EB137A13-7C6D-4728-9130-729BA5344212Q36285296-50B128F9-B291-4E5F-A6CE-34B01B48CF9EQ36907762-AEEE39F3-5A74-42E1-A83C-295E2EC11AD7Q36924378-B161DD18-AFBC-4821-8D75-142055FCA7C3Q38758034-40A4FF23-0AF0-49D9-B21B-048AC59C30C6Q38823095-8281BFAC-3C34-415F-A100-A21DB70126B2Q38949355-EC77A0FC-938C-4930-8A86-47C60D4CD126Q39086386-1D1E2CAD-D007-4C45-9C22-10FF4FF311E6Q39222725-EAF0DB92-412A-4F43-AB69-431243F8270DQ42669872-0AC6BD38-73ED-4785-B286-F320E122C773Q47192015-6D5E6C7C-80F8-4839-9D53-31B91D54A4A0Q52657953-2065A3F6-DE7D-4751-A4D2-59E167743D22Q54256014-AD3049F2-BA84-4D3A-BF5B-0801695FDC4BQ55317203-ACD84EAC-134C-4877-8CEF-F87A5441753CQ58801774-F26803D8-86C2-4FB2-BA7B-50E1046190D9
P2860
Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@en
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@nl
type
label
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@en
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@nl
prefLabel
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@en
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@nl
P2093
P2860
P356
P1433
P1476
Synergistic antitumor activity ...... plification of ERBB2 and RARA.
@en
P2093
E Garattini
F Centritto
M Fratelli
P2860
P2888
P304
P356
10.1038/ONC.2011.506
P407
P577
2011-11-07T00:00:00Z
P6179
1009589077